Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is expected to outperform the market due to its strong product portfolio, with DefenCath being a revolutionary catheter lock solution that has shown significant reduction in infection rates. Additionally, the positive data from the Ph.3 ReSPECT study further solidified Rezzayo's potential in the prophylaxis market, with a projected peak revenue of $220 million in 2034. With the potential for multiple label expansions in TPN, oncology, and pediatric hemodialysis, Cormedix has the potential for significant revenue growth in the future. Despite facing some challenges in commercial execution, competition, and potential label expansion approval, the overall positive outlook for Cormedix's products and potential for revenue diversification make it a promising investment opportunity.

Bears say

Cormedix is facing several significant challenges that could negatively impact their stock outlook in the future. These include potential delays or setbacks in the FDA approval process for their product Rezzayo in the prophylaxis indication, as well as potential enrollment challenges or negative results in clinical trials for DefenCath's label expansion into pediatric hemodialysis. The company also faces concentration and pricing risks with their primary customer and could experience a significant decline in stock valuation if their product fails to gain traction in the market.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.